Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998)

P. H. Wiernik, Elisabeth M. Paietta, O. Goloubeva, S. J. Lee, Della F. Makower, J. M. Bennett, J. L. Wade, C. Ghosh, L. S. Kaminer, J. Pizzolo, M. S. Tallman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The Eastern Cooperative Oncology Group (ECOG) performed a phase 2 study in B-cell chronic lymphocytic leukemia (CLL) of oral theophylline, a methylxanthine that inhibits cyclic nucleotide phosphodiesterases, thereby inducing the intracellular accumulation of cyclic adenosine monophosphate (cAMP). In 25 patients with Rai stages 0-I, theophylline, 200 mg given orally every 12 h was well tolerated. There was one complete response after 22.5 months of treatment, which continues at 27 + months, and 18 other patients had stable disease. In vitro exposure of patients' lymphocytes to aminophylline (75-250 μg/ml), the soluble form of theophylline, resulted in dose- and time-dependent induction of apoptosis in 9/20 patients studied. Apoptosis was documented flow-cytometrically by monitoring the expression of bcl-2 and bax, forward light scatter, fluorescence intensity of binding of CD45 antibody, and the binding of annexin. Patients whose leukemic lymphocytes were susceptible to apoptosis induction by aminophylline in vitro experienced a significantly longer progression-free survival than patients whose cells were resistant to the drug in culture (P=0.025). This suggests that in a CLL population treated with theophylline, induction of an apoptotic response to the drug in vitro is prognostic for absence of clinical progression.

Original languageEnglish (US)
Pages (from-to)1605-1610
Number of pages6
JournalLeukemia
Volume18
Issue number10
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Theophylline
Aminophylline
Apoptosis
Lymphocytes
Annexins
Cyclic Nucleotides
Phosphoric Diester Hydrolases
Pharmaceutical Preparations
Cyclic AMP
Disease-Free Survival
Fluorescence
Light
Antibodies
Population
In Vitro Techniques

Keywords

  • Apoptosis
  • B-cell CLL
  • Theophylline

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Phase II study of theophylline in chronic lymphocytic leukemia : A study of the Eastern Cooperative Oncology Group (E4998). / Wiernik, P. H.; Paietta, Elisabeth M.; Goloubeva, O.; Lee, S. J.; Makower, Della F.; Bennett, J. M.; Wade, J. L.; Ghosh, C.; Kaminer, L. S.; Pizzolo, J.; Tallman, M. S.

In: Leukemia, Vol. 18, No. 10, 10.2004, p. 1605-1610.

Research output: Contribution to journalArticle

Wiernik, PH, Paietta, EM, Goloubeva, O, Lee, SJ, Makower, DF, Bennett, JM, Wade, JL, Ghosh, C, Kaminer, LS, Pizzolo, J & Tallman, MS 2004, 'Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998)', Leukemia, vol. 18, no. 10, pp. 1605-1610. https://doi.org/10.1038/sj.leu.2403494
Wiernik, P. H. ; Paietta, Elisabeth M. ; Goloubeva, O. ; Lee, S. J. ; Makower, Della F. ; Bennett, J. M. ; Wade, J. L. ; Ghosh, C. ; Kaminer, L. S. ; Pizzolo, J. ; Tallman, M. S. / Phase II study of theophylline in chronic lymphocytic leukemia : A study of the Eastern Cooperative Oncology Group (E4998). In: Leukemia. 2004 ; Vol. 18, No. 10. pp. 1605-1610.
@article{6c5c84a0ac264bdb997977638c0e1e7c,
title = "Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998)",
abstract = "The Eastern Cooperative Oncology Group (ECOG) performed a phase 2 study in B-cell chronic lymphocytic leukemia (CLL) of oral theophylline, a methylxanthine that inhibits cyclic nucleotide phosphodiesterases, thereby inducing the intracellular accumulation of cyclic adenosine monophosphate (cAMP). In 25 patients with Rai stages 0-I, theophylline, 200 mg given orally every 12 h was well tolerated. There was one complete response after 22.5 months of treatment, which continues at 27 + months, and 18 other patients had stable disease. In vitro exposure of patients' lymphocytes to aminophylline (75-250 μg/ml), the soluble form of theophylline, resulted in dose- and time-dependent induction of apoptosis in 9/20 patients studied. Apoptosis was documented flow-cytometrically by monitoring the expression of bcl-2 and bax, forward light scatter, fluorescence intensity of binding of CD45 antibody, and the binding of annexin. Patients whose leukemic lymphocytes were susceptible to apoptosis induction by aminophylline in vitro experienced a significantly longer progression-free survival than patients whose cells were resistant to the drug in culture (P=0.025). This suggests that in a CLL population treated with theophylline, induction of an apoptotic response to the drug in vitro is prognostic for absence of clinical progression.",
keywords = "Apoptosis, B-cell CLL, Theophylline",
author = "Wiernik, {P. H.} and Paietta, {Elisabeth M.} and O. Goloubeva and Lee, {S. J.} and Makower, {Della F.} and Bennett, {J. M.} and Wade, {J. L.} and C. Ghosh and Kaminer, {L. S.} and J. Pizzolo and Tallman, {M. S.}",
year = "2004",
month = "10",
doi = "10.1038/sj.leu.2403494",
language = "English (US)",
volume = "18",
pages = "1605--1610",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Phase II study of theophylline in chronic lymphocytic leukemia

T2 - A study of the Eastern Cooperative Oncology Group (E4998)

AU - Wiernik, P. H.

AU - Paietta, Elisabeth M.

AU - Goloubeva, O.

AU - Lee, S. J.

AU - Makower, Della F.

AU - Bennett, J. M.

AU - Wade, J. L.

AU - Ghosh, C.

AU - Kaminer, L. S.

AU - Pizzolo, J.

AU - Tallman, M. S.

PY - 2004/10

Y1 - 2004/10

N2 - The Eastern Cooperative Oncology Group (ECOG) performed a phase 2 study in B-cell chronic lymphocytic leukemia (CLL) of oral theophylline, a methylxanthine that inhibits cyclic nucleotide phosphodiesterases, thereby inducing the intracellular accumulation of cyclic adenosine monophosphate (cAMP). In 25 patients with Rai stages 0-I, theophylline, 200 mg given orally every 12 h was well tolerated. There was one complete response after 22.5 months of treatment, which continues at 27 + months, and 18 other patients had stable disease. In vitro exposure of patients' lymphocytes to aminophylline (75-250 μg/ml), the soluble form of theophylline, resulted in dose- and time-dependent induction of apoptosis in 9/20 patients studied. Apoptosis was documented flow-cytometrically by monitoring the expression of bcl-2 and bax, forward light scatter, fluorescence intensity of binding of CD45 antibody, and the binding of annexin. Patients whose leukemic lymphocytes were susceptible to apoptosis induction by aminophylline in vitro experienced a significantly longer progression-free survival than patients whose cells were resistant to the drug in culture (P=0.025). This suggests that in a CLL population treated with theophylline, induction of an apoptotic response to the drug in vitro is prognostic for absence of clinical progression.

AB - The Eastern Cooperative Oncology Group (ECOG) performed a phase 2 study in B-cell chronic lymphocytic leukemia (CLL) of oral theophylline, a methylxanthine that inhibits cyclic nucleotide phosphodiesterases, thereby inducing the intracellular accumulation of cyclic adenosine monophosphate (cAMP). In 25 patients with Rai stages 0-I, theophylline, 200 mg given orally every 12 h was well tolerated. There was one complete response after 22.5 months of treatment, which continues at 27 + months, and 18 other patients had stable disease. In vitro exposure of patients' lymphocytes to aminophylline (75-250 μg/ml), the soluble form of theophylline, resulted in dose- and time-dependent induction of apoptosis in 9/20 patients studied. Apoptosis was documented flow-cytometrically by monitoring the expression of bcl-2 and bax, forward light scatter, fluorescence intensity of binding of CD45 antibody, and the binding of annexin. Patients whose leukemic lymphocytes were susceptible to apoptosis induction by aminophylline in vitro experienced a significantly longer progression-free survival than patients whose cells were resistant to the drug in culture (P=0.025). This suggests that in a CLL population treated with theophylline, induction of an apoptotic response to the drug in vitro is prognostic for absence of clinical progression.

KW - Apoptosis

KW - B-cell CLL

KW - Theophylline

UR - http://www.scopus.com/inward/record.url?scp=6344282963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344282963&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403494

DO - 10.1038/sj.leu.2403494

M3 - Article

C2 - 15356646

AN - SCOPUS:6344282963

VL - 18

SP - 1605

EP - 1610

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -